Abdera Therapeutics
Michelle Chan is an accomplished Associate Scientist at Abdera Therapeutics since September 2024, with prior experience as an Associate Research Scientist at AbCellera from March 2020 to September 2024. Previous roles include Production Technician at AbCellera and Student Researcher at BC Cancer, where research focused on the sensitization of the MDA-MB-321 triple negative breast cancer cell line. Further experience includes a Lab Volunteer position at Simon Fraser University, where genomic DNA preparation and plasmid extraction were performed, and a CO-OP Research Assistant role, where activities included screening P450cam mutants and protein purification. Michelle holds an Honours Bachelor of Science in Molecular Biology and Biochemistry from Simon Fraser University and completed an American Degree Program in Biosciences at HELP University.
This person is not in any teams
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.